This is an in-house study for patients with Relapsing-Remitting Multiple Sclerosis (RR-MS) dealing with constipation, gastroparesis. You will be provided with a free bottle of Parasym Plus™ and asked for a diary of bowel movements — it’s that easy!
What is Parasym Plus™?
Parasym Plus™ is a new supplement mix with two patents to date. It is uniquely designed to support acetylcholine — the neurotransmitter required by the vagus nerve to assist every aspect of digestion — including bowel movements and stool motility. It also crosses the blood-brain barrier to provide acetylcholine for short-term memory and cognition.
What is the vagus nerve?
The vagus nerve is part of the parasympathetic nervous system — the “rest and digest” system of the body. It allows the heart and breathing to slow and to calm anxiousness (it allows us to “rest”). It also controls digestion — from normal stomach acid production to gallbladder and pancreatic function and motility (it allows us to “digest”). When not functioning optimally, nutrient malabsorption, constipation, and even gastroparesis can occur.
The vagus nerve is also the anti-inflammatory nerve of the body and if not working correctly, chronic inflammation can result.
The vagus nerve utilizes acetylcholine, a neurotransmitter, to communicate with both organs and immune cells. When acetylcholine levels are reduced for any reason, vagus nerve function declines.
Why should Parasym Plus™ help those with Relapsing-Remitting Multiple Sclerosis?
Patients with Multiple Sclerosis have been found to have significantly reduced levels of acetylcholine in both the blood and the cerebrospinal fluid (the fluid surrounding the brain and spinal cord). When acetylcholine is low, the function of the vagus nerve is affected. This results in constipation (or gastroparesis), nutrient malabsorption, and increased inflammation.
It has also been found that in patients with Multiple Sclerosis, the lower the acetylcholine levels, the higher the levels of damaging inflammatory cytokines present. Multiple Sclerosis is an inflammatory condition affecting immune cells and nerves. Normally, acetylcholine utilized by the vagus nerve helps control inflammation. When acetylcholine release is not optimal, increased inflammation results.
Previously, constipation/gastroparesis in Multiple Sclerosis patients was assumed to be due to demyelination of the nerves or due to spinal cord damage. But the new research in acetylcholine levels in Multiple Sclerosis suggests that for many patients, these symptoms may be treatable with acetylcholine support.
What is involved in this study?
This is an in-house study of an existing supplement mix with ingredients already deemed safe by the FDA. If you qualify, we will send you a free bottle of Parasym Plus™ and ask you to record your bowel movements over two weeks. We will also ask you if you experienced any other benefits (such as improved cognition, short-term memory, or increased energy). If you are taking prescription medication, you should not stop your medication. As is true with any supplements, please check with your health care provider concerning its use.
Comment from the inventor:
“I often heard from multiple sclerosis patients that constipation or gastroparesis was one of their first symptoms! I thought that demyelination may not have yet occurred, and perhaps there were other reasons for that presentation. Vagus nerve problems due to low acetylcholine levels are easy to miss because there is no blood test for it. But too often, patients are told that all of their symptoms are “because they have MS”. By thinking deeper, we can often help patients and dramatically improve their quality of life.”
— Diana Driscoll, President Genetic Disease Investigators, LLC
What to do now:
Submit your qualifying questionnaire to see if you qualify here. This study is limited to the first 25 people who qualify.
For more information about Parasym Plus™, visit https://vagusnervesupport.com/vagus-nerve-support-parasym-plus/
Di Bari, Maria, et al. “Dysregulated homeostasis of acetylcholine levels in immune cells of RR-multiple sclerosis patients.” International journal of molecular sciences 17.12 (2016): 2009.
Reale, Marcella, et al. “Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients.” International journal of molecular sciences 13.10 (2012): 12656-12664.
Di Bari, Maria, et al. “Cholinergic system and neuroinflammation: implication in multiple sclerosis.” Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents) 17.2 (2017): 109-115.
Kooi, Evert-Jan, et al. “Cholinergic imbalance in the multiple sclerosis hippocampus.” Acta neuropathologica 122.3 (2011): 313-322.
Levinthal, David J., et al. “Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis.” Multiple sclerosis international 2013 (2013).
Reddymasu, Savio C., John Bonino, and Richard W. McCallum. “Gastroparesis secondary to a demyelinating disease: a case series.” BMC gastroenterology 7.1 (2007): 3.
Polachini, Carla Roberta Nunes, et al. “Cholinergic and purinergic systems: A key to multiple sclerosis?.” Journal of the neurological sciences 392 (2018): 8-21.Millet, Treinin, et al. “Role of the α7 nicotinic acetylcholine receptor and RIC-3 in the cholinergic anti-inflammatory pathway.” Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents) 17.2 (2017): 90-99.